

ASX Release

## Appointment of non-executive Directors to the Board of Ascent Pharmahealth

**12th August 2008, Melbourne:** Ascent Pharmahealth Limited (ASX:APH) today announced the appointment of Mr Arun Kumar and Mr Ravi Seth as non-executive directors.

Mr Kumar is the co-founder and Group CEO of Strides Arcolab Limited (a listed company on the National Stock Exchange of India and Bombay Stock Exchange Limited) and has been a Director since its inception in 1990. After graduating in Commerce, Mr Kumar began his career with one of India's earliest exporters of pharmaceuticals in the early 1980's. Mr Kumar has substantial experience in the international pharmaceutical market and has developed close associations with a large number of the world's leading international pharmaceutical companies including the establishment of commercial joint venture partnerships with Aspen Pharmacare and GlaxoSmithKline.

Mr Seth obtained his Bachelors Degree in Science in 1981 with specialisations in Mathematics and Statistics and subsequently qualified as a Chartered Accountant with the Institute of Chartered Accountants in India in 1985. During this career spanning 20 years he worked in a number of industries including Hotels, Financial Services, Real Estate, Media and Pharmaceuticals. Mr Seth joined Strides Arcolab Limited in May 2006 as Group CFO where his major focus areas were the creation of a global support infrastructure, fund raising and growth. In March 2008 Mr Seth became CEO – International Operations of Strides Arcolab Limited with responsibility for all global operations and Joint Ventures.

Mr Tom O'Brien, chairman of Genepharm says: "The board welcomes Arun Kumar and Ravi Seth to Ascent. Their combined experience in the international pharmaceutical markets and their support as representatives of Strides, our majority shareholder, will strengthen our Board."

### **Enquiries:**

**Dennis Bastas**  
**Ascent Pharmahealth**  
**03 8677 6600**

### **About Ascent Pharma:**

Ascent Pharmahealth (ASX:APH) is a growth-oriented pharmahealth company with a particular focus on generic pharmaceuticals. Ascent markets, sells and distributes a range of healthcare products ranging from blockbuster prescription drugs to cosmeceuticals in Australia and key Asian markets including Singapore, Hong Kong, Malaysia, Thailand and Vietnam. Ascent's key subsidiaries are Genepharm, Australia's 3rd largest generic pharmaceutical company and Drug Houses of Australia, Singapore's largest generic pharmaceutical company. The company was established in 2003 as Genepharm Australasia and listed on the ASX in 2004.

For more info: [www.ascentpharma.com.au](http://www.ascentpharma.com.au).

For personal use only

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>ASCENT PHARMAHEALTH LIMITED</b>
<b>ABN</b>	<b>52 107 340 367</b>

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>ARUN KUMAR</b>
<b>Date of appointment</b>	<b>31 JULY 2008</b>

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
Not Applicable

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3X**  
**Initial Director's Interest Notice**

**Part 2 – Director's relevant interests in securities of which the director is not the registered holder**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b>	<b>Number &amp; class of Securities</b>
<p>Note: Provide details of the circumstances giving rise to the relevant interest.</p> <p>Strides Arcolab Limited:</p> <ul style="list-style-type: none"> <li>○ in which Arun Kumar has a beneficial interest</li> <li>○ which has a deemed relevant interest under s608(3) of the <i>Corporations Act 2001</i> in Linkace Limited, a substantial holder of Ascent Pharmahealth Limited; and</li> <li>○ which is the ultimate holding company of Ascent Pharmahealth Limited and Linkace Limited</li> </ul> <p>Linkace Limited in which Arun Kumar has a beneficial interest</p>	<p>111,157,023 Ordinary Shares</p>

**Part 3 – Director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Preferred Supply Agreement between Strides Arcolab Limited and Strides Singapore Pte Limited (a subsidiary of Ascent Pharmahealth Limited)
<b>Nature of interest</b>	Arun Kumar holds 3.08% of the issued equity in Strides Arcolab Limited
<b>Name of registered holder (if issued securities)</b>	Not Applicable
<b>No. and class of securities to which interest relates</b>	Not Applicable

+ See chapter 19 for defined terms.

For personal use only

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>ASCENT PHARMAHEALTH LIMITED</b>
<b>ABN</b>	<b>52 107 340 367</b>

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	<b>RAVI SETH</b>
<b>Date of appointment</b>	<b>31 JULY 2008</b>

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
Not Applicable

+ See chapter 19 for defined terms.

For personal use only

**Appendix 3X**  
**Initial Director's Interest Notice**

**Part 2 – Director's relevant interests in securities of which the director is not the registered holder**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Name of holder & nature of interest	Number & class of Securities
<p>Note: Provide details of the circumstances giving rise to the relevant interest.</p> <p>Strides Arcolab Limited:</p> <ul style="list-style-type: none"> <li>○ of which Ravi Seth has a beneficial interest; and</li> <li>○ of which has a deemed relevant interest under s608(3) of the <i>Corporations Act 2001</i> in Linkace Limited, a substantial holder of Ascent Pharmahealth Limited</li> </ul>	<p>111,157,023 Ordinary Shares</p>

**Part 3 – Director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Preferred Supply Agreement between Strides Arcolab Limited and Strides Singapore Pte Limited (a subsidiary of Ascent Pharmahealth Limited)
<b>Nature of interest</b>	Ravi Seth holds 180,000 Employee Stock Options in Strides Arcolab Limited
<b>Name of registered holder (if issued securities)</b>	Not Applicable
<b>No. and class of securities to which interest relates</b>	Not Applicable

+ See chapter 19 for defined terms.

For personal use only